Aardvark Therapeutics (AARD) Retained Earnings (2025 - 2026)
Aardvark Therapeutics (AARD) posted Retained Earnings of -$137.5 million for Q1 2026, down 169860.49% sequentially from $81000.0 in Q4 2025, and down 312613.64% YoY from N/an in Q1 2025.
Aardvark Therapeutics (AARD) Retained Earnings (2025 - 2026) Analysis & Trends
Aardvark Therapeutics has reported Retained Earnings for 2 years, with the latest figure at -$137.5 million in Q1 2026.
- Quarterly Retained Earnings fell 312613.64% year-over-year to -$137.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$137.5 million (down 312613.64% YoY) and the FY2025 annual result came in at $81000.0, changed N/A from the prior year.
- Retained Earnings fell to -$137.5 million in Q1 2026 per AARD's latest filing, from $81000.0 in the prior quarter.
- Over five years, Retained Earnings peaked at $82000.0 in Q3 2025 and troughed at -$137.5 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Aardvark Therapeutics | 147.46 Mn | 73.54 Mn | - | -151.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -151.90 Mn |
| Mar 31, 2026 | -137.51 Mn |
| Dec 31, 2025 | 81,000.00 |
| Sep 30, 2025 | 82,000.00 |
| Jun 30, 2025 | -3,000.00 |
| Mar 31, 2025 | 44,000.00 |